EBS - Altimmune Declines Too Much
Currently trading at 0.52x its book value per share after several equity transactions, Altimmune (ALT) seems a bit undervalued as compared to peers. The company sold large amount of warrants that investors should not appreciate. With that, other peers are trading at 1.95x-4.4x book value per share. So, a share price rebound could be possible on this name. An affiliate of Novartis invested in the company, which the market should appreciate.
Business
Founded in 1997 and headquartered in Gaithersburg, Maryland, Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended